|
|
|
| The Applications of Cyclodextrins and Their Derivatives in Non-injection Administration Systems of Peptide/Protein Drugs |
| CHEN Xing-yu, XIN Jian-yu, LI Jian-shu |
| College of Polymer Science and Engineering, Sichuan University, Chengdu 610065, China |
|
|
|
Abstract Nowadays, peptide/protein drugs are administrated by injective formulations to ensure their bioavailability. While non-injection formulations, particularly oral delivery method, are desiderata because they exhibit great advantages such as easier administration, better patient compliance and lower cost. However, the bioavailability is usually very low if the peptide/protein drugs are used directly in the non-injection systems. And it is necessary to develop drug delivery systems with designed functions, such as adding different proportions of the protease inhibitors and/or absorption enhancers to improve drug bioavailability. Cyclodextrins(CDs) and their derivatives can form complexes with various molecules and have the capability to facilitate mucosa permeability, thus are widely applied in the non-injection administration systems of peptide/protein drugs. recent applications of CDs and their derivatives in non-injection administration systems of peptide/protein drugs were reviewed.
|
|
Received: 11 August 2010
Published: 25 December 2010
|
|
|
|
|
| [1] |
梅兴国.药物新剂型与制剂新技术.北京:化学工业出版社,2007.241-265. Mei X G. Advanced Drug Delivery System: New Technology and Dosage Form. Beijing: Chemical Industry Press, 2007. 241-265.
|
|
|
| [2] |
Szejtli J. Introduction and general overview of cyclodextrin chemistry. Chem Rev, 1998,98(5):1743-1753.
|
|
|
| [3] |
Sajeesh S, Sharma C P. Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. Int J Pharm, 2006,325(1-2):147-154.
|
|
|
| [4] |
Moses L R, Dileep K J, Sharma C P. Beta cyclodextrin-insulin-encapsulated chitosan/alginate matrix: Oral delivery system. J Appl Polym Sci, 2000,75(9): 1089-1096.
|
|
|
| [5] |
Denadai A M, Ianzer D, Alcantara A F, et al. Novel pharmaceutical composition of bradykinin potentiating penta peptide with beta-cyclodextrin: Physical-chemical characterization and anti-hypertensive evaluation. Int J Pharm, 2007,336(1): 90-98.
|
|
|
| [6] |
黄可可.蛋白质药物的海藻酸钙/壳聚糖微球控释载体制备及性能研究.西安:西北大学,2006. Huang K K. Preparation of calcium alginate/chitosan microsphere for protein oral delivery and its properties study. Xi’an: Northwestern University, 2006.
|
|
|
| [7] |
Leonard M, De Boisseson A R, Hubert P, et al. Hydrophobically modified alginate hydrogels as protein carriers with specific controlled release properties. J Control Release, 2004,98(3):395-405.
|
|
|
| [8] |
Sarmento B, Ferreira D C, Jorgensen L, et al. Probing insulin’s secondary structure after entrapment into alginate/chitosan nanoparticles. Eur J Pharm Biopharm, 2007,65(1):10-17.
|
|
|
| [9] |
Radwan M A, Aboul-Enein H Y. The effect of oral absorption enhancers on the in vivo performance of insulin-loaded poly(ethylcyanoacrylate) nanospheres in diabetic rats. J Microencapsul, 2002,19(2):225-235.
|
|
|
| [10] |
Xin J Y, Guo Z Z, Chen X Y, et al.. Study of branched cationic β-cyclodextrin polymer/indomethacin complex and its release profile from alginate hydrogel. Int J Pharm, 2010,386(1-2):221-228.
|
|
|
| [11] |
Huang L, Xin J Y, Guo Y C, et al. A novel insulin oral delivery system assisted by cationic β-cyclodextrin polymers. J Appl Polym Sci, 2010,115(3):1371-1379.
|
|
|
| [12] |
Zhang N, Li J H, Jiang W F, et al. Effective protection and controlled release of insulin by cationic β-cyclodextrin polymers from alginate/chitosan nanoparticles. Int J Pharm, 2010,393(1-2):212-218.
|
|
|
| [13] |
Palamakula A, Shah R B, Khan M A. Cytotoxicity evaluation of enzyme inhibitors and absorption enhancers in Caco-2 cells for oral delivery of salmon calcitonin. J Pharm Sci, 2004,93(4):1070-1082.
|
|
|
| [14] |
Trapani A, Laquintana V, Denora N, et al. Eudragit RS 100 microparticles containing 2-hydroxypropyl-beta-cyclodextrin and glutathione: Physicochemical characterization, drug release and transport studies. Eur J Pharm Sci, 2007,30(1): 64-74.
|
|
|
| [15] |
Garcia-Fuentes M, Trapani A, Alonso M J. Protection of the peptide glutathione by complex formation with alpha-cyclodextrin: NMR spectroscopic analysis and stability study. Eur J Pharm Biopharm, 2006,64(2):146-153.
|
|
|
| [16] |
Cui C Y, Lu W L, Xiao L, et al. Sublingual delivery of insulin: Effects of enhancers on the mucosal lipid fluidity and protein conformation, transport, and in vivo hypoglycemic activity. Biol Pharm Bull, 2005,28(12):2279-2288.
|
|
|
| [17] |
Merkus F W, Verhoef J C, Marttin E, et al. Cyclodextrins in nasal drug delivery. Adv Drug Deliver Rev, 1999,36(1): 41-57.
|
|
|
| [18] |
Hussain A, Arnold J J, Khan M A, et al. Absorption enhancers in pulmonary protein delivery. J Control Release, 2004,94(1): 15-24.
|
|
|
| [19] |
Kinnarinen T, Jarho P, Jrvinen K, et al. Pulmonary deposition of a budesonide/γ-cyclodextrin complex in vitro. J Control Release, 2003,90(2): 197-205.
|
|
|
| [20] |
Martins S, Sarmento B, Souto E B, et al. Insulin-loaded alginate microspheres for oral delivery——Effect of polysaccharide reinforcement on physicochemical properties and release profile. Carbohyd Polym, 2007,69(4):725-731.
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
